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 Patient: Male, 58
 Final Diagnosis: Prostate cancer
 Symptoms: Testicular mass
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 Specialty: Oncology
 Objective: Unusual clinical course
 Background: Prostatic adenocarcinoma is the most frequently diagnosed carcinoma in the male population; the most com-
mon sites of secondary lesions are nodes, bones, and lungs. We report the clinical case of a 58-year-old man 
presenting with a single metastasis in the left testis after a radical prostatectomy/lymphadenectomy for pros-
tate cancer.
 Case Report: This clinical report focuses on a 58-year-old man with prostate cancer who developed an uncommon single 
metastasis in the left testis after radical surgery and adjuvant pelvic radiation therapy.
 Conclusions: Prostate-specific antigen (PSA) levels are important in the follow-up of prostate cancer. At the same time, phys-
ical examination of all possible sites of metastasis and proper evaluation of all signs/symptoms are indispens-
able in the process of identifying recurrence and for the selection of patients undergoing adjuvant therapy.
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Background
Prostatic adenocarcinoma is the most frequently diagnosed 
carcinoma in the male population; the most common sites of 
distant metastasis are nodes, bones, and lungs. Metastases 
to the testis are rare events with less than a 4% incidence 
rate [1]. This type of metastasis is usually unilateral, present-
ing as a palpable testicular mass, and rarely has simultaneous 
involvement of testis and epididymis [2].
While several studies have described dissemination of meta-
static prostate cancer to testis [3], only a few studies have re-
ported an isolated testicular metastasis from prostate cancer 
after radical prostatectomy [4–7]. Here, we discuss the clini-
cal case of a man presenting with a single recurrence in the 
left testis after a radical prostatectomy/lymphadenectomy for 
prostate cancer.
Case Report
A 58-year-old man presented with a prostate-specific antigen 
(PSA) level of 7.6 ng/mL. His physical examination was normal, 
while, a digital rectal exam revealed a hard nodule in the left 
prostate lobe. A prostate biopsy was performed and revealed 
an adenocarcinoma of the prostate with Gleason score (GS) 
of 9 (4+5). Subsequent chest-abdomen computed tomogra-
phy (CT) and bone scan confirmed the prostate lesion with no 
evidence of distant metastasis; the patient was treated with a 
radical prostatectomy/lymphadenectomy. The pathologic stage 
was pT3b R1 (with positive margin) pN0 (0/7) cM0, GS 9 (4+5). 
Although serum PSA levels at one and three months after sur-
gery were undetectable, the patient started adjuvant radia-
tion therapy with volumetric modulated arc therapy (VMAT) 
and simultaneous integrated boost (SIB) technique [8] on the 
prostatic bed (30 fractions of 2.3 Gy up to 69 Gy) and on the 
pelvic lymph nodes (30 fraction of 1.75 Gy up to 54.25 Gy) for 
the positivity of the margin (R1). As the patient was consid-
ered “high risk”, adjuvant hormone-therapy with androgen de-
privation therapy was proposed, but the patient declined con-
sent to treatment. Regular follow-up was carried out without 
signs of biochemical or clinical relapse until the 32 months’ 
visit; at this time-point, a biochemical progression was seen, 
with a PSA of 0.61 ng/mL. The re-staging exams (pelvic mag-
netic resonance imaging (MRI), C-11 choline positron emis-
sion tomography (PET) scan) were negative; however, a mass 
of 1.5 cm was clinically detected in the left testis. After radi-
cal orchiectomy, the pathology report confirmed the presence 
of a metastatic lesion from the prostatic adenocarcinoma (GS 
5+4). The patient declined consent to adjuvant hormone-ther-
apy and was reviewed at regular intervals for follow-up. Five 
years from the metastasis’ resection, the patient is still dis-
ease-free with a PSA of 0.01 ng/mL.
Discussion
The most frequent site of metastasis for prostate cancer is 
the bone (84% of the cases), followed by distant lymph nodes 
(10.6%), liver (10.2%), and lungs (9.1%) [3]. Testicular metas-
tases from primary prostate carcinoma are very rare, ranging 
between 0.18% and 0.5%, and their diagnosis can pose great 
difficulties [9]. In fact, they are often an incidental finding dur-
ing therapeutic orchiectomy in patients with advanced pros-
tatic cancer or during autopsy. Moreover, with the advent of 
luteinizing hormone-releasing hormone (LH/RH) analogues, 
the orchiectomy has been almost completely abandoned and 
therefore detection of this type of incidental secondary has 
become even rarer; morphological changes of the testes or re-
lated signs and symptoms are the only findings that may help 
in the diagnostic process. Several authors believe that a sol-
itary metastasis to the testis from prostate cancer could be 
facilitated by the unique lymphatic anatomic connections be-
tween the prostate and the testicle [5] or could originate from 
malignant lesions of the prostatic urethra by retrograde ve-
nous extension [6,10,11].
The histological features of testicular metastases from prostate 
cancer are similar to those of primary prostate cancers; rarely, 
however, histology may show a more aggressive phenotype [12] 
with high risk of further cancer spreading [13] and, thus, de-
creased survival. Weitzner et al. and Lu et al. [14,15] reported 
a median survival of about 12 months in patients with newly 
diagnosed testicular metastases from prostate cancer. On the 
other hand, other studies have reported a survival longer than 
two years in the absence of biochemical relapses. Therefore, 
the prognostic role of testicular metastases from prostate can-
cer is still unknown, mainly as a consequence of the rarity of 
the event [6]. In the current case, the patient is still alive af-
ter five years, with no evidence of disease and undetectable 
PSA levels after monolateral orchiectomy, and without under-
going any adjuvant systemic therapy.
In the literature, a few studies have reported an isolated me-
tastasis from prostate cancer after radical prostatectomy [4–7]. 
Most of these published cases described high GS prostate can-
cers [4,6]. In line with these data, our patient presented with 
GS 9 prostate cancer. It is well known that the GS serves as 
a predictor of the final pathological stage and prognosis [16]. 
However, it is difficult to define GS predictive role in the case 
of isolated testis metastases from prostate cancer after rad-
ical prostatectomy.
Due to disease stage and R1, our patient underwent adjuvant 
radiation therapy, as previously reported in a similar case [6]. 
In addition, although our patient declined consent to adjuvant 
hormone-therapy, the role of this approach in the prevention 
of isolated testis metastasis is unclear [6,7].
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PSA levels are commonly considered the most accurate marker 
of recurrence and/or progression and therefore strictly moni-
tored in follow-up [17]. In line with this, our patient showed an 
increase in PSA levels, as reported in other published case re-
ports [5,7]. Unfortunately it remains difficult to confirm wheth-
er a specific trend in the rising of PSA could suggest the pos-
sibility of an isolated metastasis to the testis.
Finally, literature data showed that the time from radical pros-
tatectomy to diagnosis of isolated testis metastasis may range 
from 6 months [4] to several years [7]; (32 months from pre-
vious radical surgery in our case).
The best therapeutic approach after orchiectomy in the ab-
sence of other metastases is still controversial. It is conceivable 
that a solitary secondary localization to the testis from pros-
tate cancer could possibly have limited spreading potential; 
on the other hand, it may constitute an intermediate phase in 
the pathway to the acquisition of the characteristics of inva-
siveness which would lead to systemic dissemination. In par-
ticular, it is unknown if a strict monitoring-only policy would 
be safe after a clinical and biochemical complete remission or 
if administration of “adjuvant” treatment is necessary, as rec-
ommended by Kwon et al. [6]. Additionally, the role of other 
local therapy in the form of radiotherapy remains particularly 
controversial as there is not enough evidence due to the rar-
ity of the situation.
To help with the decision-making process and patient man-
agement, we feel it is important to consider the clinical-path-
ological features along with the underlying molecular aber-
rations of the tumor on a case-to-case basis. An appropriate 
approach certainly requires a careful analysis which should 
take into account the clinical status, the biological character-
istics of the tumor and the PSA levels during the course of the 
disease, before and after the orchiectomy.
Conclusions
PSA level monitoring plays an essential part in the follow-up 
of prostate cancer patients. However, to help with the deci-
sion-making process and patient management, we feel it is im-
portant to consider the clinical-pathological features, togeth-
er with the biological characteristics of the tumor, in parallel 
with the progress of the PSA levels during the course of the 
disease. Nonetheless, physical examination of all sites of me-
tastasis and accurate evaluation of all signs/symptoms dur-
ing the clinical visit remains crucial to the diagnosis of recur-
rence. Testicular metastases need to be considered as a sign 
of prostate cancer progression and an adequate therapy, tai-
lored to suit each patient’s needs, is required.
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